[{"id":"9561390b-a03a-41cf-b8b2-50b5f839c95f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05665062","created_at":"2022-12-27T15:59:01.920Z","updated_at":"2024-07-02T16:35:13.523Z","phase":"Phase 1","brief_title":"Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies","source_id_and_acronym":"NCT05665062","lead_sponsor":"Synthekine","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • STK-009/SYNCAR-001"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/24/2022","start_date":" 06/24/2022","primary_txt":" Primary completion: 06/24/2026","primary_completion_date":" 06/24/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-21"}]